KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY).

Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, Bahar Ahani, Yue Chang, Ron Dagan, Mark T Esser, Laura L Hammitt, Vaishali S Mankad, Xavier Saez-Llorens, David Shen, Amanda Leach, Elizabeth J Kelly, Tonya Villafana, Deidre Wilkins

Clin Infect Dis 81(3) 634-644

PMID39656748
PMCIDPMC12497957
DOI10.1093/cid/ciae596
发表日期2024-12-10
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 multi panel km;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Nirsevimab is an extended half-life, highly potent, anti-respiratory syncytial virus (RSV) fusion protein neutralizing monoclonal antibody with efficacy against RSV-associated medically attended (MA) lower respiratory tract infection (LRTI) in infants and medically vulnerable children (aged ≤24 months). This post hoc exploratory analysis examined the incidence of LRTI from RSV and other respiratory pathogens during MELODY: a 2:1 randomized, double-blind, placebo-controlled, phase 3 study of nirsevimab in healthy term and late preterm (ie, gestational age ≥35 weeks) infants entering their first RSV season. METHODS: A total of 3012 participants were randomized to nirsevimab (n = 2009) or placebo (n = 1003). Nasopharyngeal swabs were collected from infants who presented with an LRTI and tested for 22 different respiratory pathogens using the BioFire® Respiratory 2.1 Panel. Incidence of RSV and non-RSV MA-LRTIs through day 511 and LRTI severity were assessed. RESULTS: A total of 852 nasopharyngeal swabs were collected from 561 participants through day 511: 519 swabs from 337 nirsevimab participants and 333 swabs from 224 placebo participants. RSV and non-RSV infections were detected in 193 of 852 (22.7%) and 55 of 852 (64.7%) swabs, respectively. RSV infection rates were lower with nirsevimab compared with placebo, including RSV-rhinovirus/enterovirus coinfections. Rates of other viral infections were similar between study arms. Approximately 70% of single RSV infections and RSV coinfections were adjudicated as mild, and 26.2% of single RSV infections and 24.5% of RSV coinfections required hospitalization. CONCLUSIONS: Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses. Clinical Trials Registration. NCT03979313.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/institutional-portal/clinical-infectious-diseases/tidbits/lower-respiratory-tract-infections-following-respiratory-syncytial-virus-monoclonal-antibody-nirsevimab-immunization-versus-placebo-analysis-from-a-phase-3-randomized-clinical-trial-melody/update
非 KM Figure
Figure 1Figure 1. Cumulative incidence of RSV, non-RSV–VFAPn, RV/ENT, and all non-RSV infections detected via the BioFire Respiratory 2.1 Panel in participants in the nirsevimab and placebo arms across the whole study period (day 1 to day 511). Cumulative incidences are shown at days 151, 361, and 511. Coinfections are counted in all applicable individual cumulative incidence analyses. a Analysis of any VFAPn infection is an additive analysis of cumulative incidence of human metapneumovirus, parainfluenza virus (1–4), and influenza virus (A/B) infections. b Analysis of any non-RSV infection is an additive cumulative incidence of all infections except RSV. Cumulative incidence analyses include all new-onset events as detected using the BioFire panel within the respective categories of infection; that is, an individual with 2 separate infections with the same virus is counted twice in cumulative incidence analysis for that virus. Abbreviations: ENT, enterovirus; RSV, respiratory syncytial virus; RV, rhinovirus; VFAPn, viruses frequently associated with pneumonia.
非 KM Figure
Figure 2Figure 2. Incidence of first episodes of infection for each virus, regardless of type of infection (“All” = single infection or coinfection) or excluding coinfections (“Single infection”) for RSV and RV/ENT, through day 151 ( A ) and day 511 ( B ). Abbreviations: AdV, adenovirus; ENT, enterovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; RSV, respiratory syncytial virus; RV, rhinovirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
非 KM Figure
Figure 3Figure 3. Incidence by calendar time of respiratory virus infections over the course of the 3-year MELODY study in participants in the nirsevimab ( A ) and placebo arms ( B ). Dashed line represents locally estimated scatterplot smoothing. Abbreviations: hCoV, human coronavirus; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
非 KM Figure
Figure 4Figure 4. Severity of respiratory illness in RSV-associated medically attended lower respiratory tract infection through day 511 by study intervention and type of infection. A , RSV only or RSV with any coinfection. B , RSV with RV/ENT coinfection or RSV with any VFAPn coinfection. a RSV coinfection includes coinfection with adenovirus, SARS-CoV-2, hCoV, human RV/ENT, and VFAPn (human metapneumovirus, influenza virus [A/B], parainfluenza virus [1–4]). b Life-threatening = requiring respiratory support by mechanical ventilation/continuous positive airway pressure (CPAP)/high-flow nasal cannula (HFNC) or pediatric intensive care unit (PICU); very severe = hospitalized for RSV lower respiratory tract infection and requirement of oxygen or intravenous (IV) supply but not requiring mechanical ventilation/CPAP/HFNC or PICU; severe = hospitalized but not requiring oxygen or IV or mechanical ventilation/CPAP/HFNC/PICU (intensive care); moderate = ReSViNET score >6 but not hospitalized; mild = ReSViNET score ≤6 but not hospitalized [17]. Abbreviations: ENT, enterovirus; hCoV, seasonal human coronavirus; ReSViNET, Respiratory Syncytial Virus Network; RSV, respiratory syncytial virus; RV, rhinovirus; SARS-CoV-2, severe actute respiratory syndrme coronavirus 2; VFAPn, viruses frequently associated with pneumonia.
非 KM Figure